&nbsp;

Drugs Used:

bortezomib (PDRP prior authorization),

lenalidomide,

dexamethasone

Quick Link(s):

Regimen Monograph

Dec 2023

Regimen

CYCLDOCE+PEMB

Cancer Type:

Breast

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2023

Regimen

CABAPRED

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

New Drug Funding Program

Cabazitaxel - Metastatic Castration Resistant Prostate Cancer

ODB - General Benefit

prednisone

Drugs Used:

cabazitaxel,

prednisone

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

NIVL

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab - Advanced or Metastatic Non-Small Cell Lung Cancer

Drugs Used:

nivolumab

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

TRAS

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer

Drugs Used:

trastuzumab

Quick Link(s):

Regimen Monograph

Feb 2023

Regimen

TRAS(MNT)

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma

Drugs Used:

trastuzumab

Quick Link(s):

Regimen Monograph

Dec 2024

Regimen

TEMS

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

New Drug Funding Program

Temsirolimus - Metastatic Renal Cell Carcinoma

Drugs Used:

temsirolimus

Quick Link(s):

Regimen Monograph

Jun 2024

Regimen

DURV(MNT)

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

New Drug Funding Program

Durvalumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

New Drug Funding Program

Durvalumab in combination with Tremelimumab - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma (HCC)

Drugs Used:

durvalumab

Quick Link(s):

Regimen Monograph

Apr 2024

Regimen

GDP+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Curative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma

ODB - General Benefit

dexamethasone

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2024

Regimen

BORTDEXAPOMA

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - In Combination with Pomalidomide and Dexamethasone for Previously Treated Multiple Myeloma

ODB - General Benefit

dexamethasone

Exceptional Access Program

pomalidomide - In combination with bortezomib and dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma, based on criteria

Drugs Used: